These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31301315)

  • 1. Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer.
    Cao F; Gong YB; Kang XH; Lu ZH; Wang Y; Zhao KL; Miao ZH; Liao MJ; Xu ZY
    Toxicol Appl Pharmacol; 2019 Sep; 379():114662. PubMed ID: 31301315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
    Shi P; Oh YT; Deng L; Zhang G; Qian G; Zhang S; Ren H; Wu G; Legendre B; Anderson E; Ramalingam SS; Owonikoko TK; Chen M; Sun SY
    Clin Cancer Res; 2017 Nov; 23(21):6567-6579. PubMed ID: 28765329
    [No Abstract]   [Full Text] [Related]  

  • 4. Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.
    Wu S; Luo M; To KKW; Zhang J; Su C; Zhang H; An S; Wang F; Chen D; Fu L
    Mol Cancer; 2021 Jan; 20(1):17. PubMed ID: 33461557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.
    Han R; Lu CH; Hu C; Dou YY; Kang J; Lin CY; Wu D; Jiang WL; Yin GQ; He Y
    Acta Pharmacol Sin; 2024 Jun; 45(6):1264-1275. PubMed ID: 38438582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol.
    Zang H; Qian G; Arbiser J; Owonikoko TK; Ramalingam SS; Fan S; Sun SY
    Mol Oncol; 2020 Apr; 14(4):882-895. PubMed ID: 32003107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
    Zang H; Qian G; Zong D; Fan S; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer; 2020 Jan; 126(9):2024-2033. PubMed ID: 31999837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC).
    Bracht JWP; Karachaliou N; Berenguer J; Pedraz-Valdunciel C; Filipska M; Codony-Servat C; Codony-Servat J; Rosell R
    Int J Biol Sci; 2019; 15(12):2607-2614. PubMed ID: 31754333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.
    La Monica S; Minari R; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Galetti M; Digiacomo G; Riccardi F; Petronini PG; Tiseo M; Alfieri R
    Target Oncol; 2019 Oct; 14(5):619-626. PubMed ID: 31502118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.
    Chen W; Yu D; Sun SY; Li F
    Acta Biomater; 2021 Jul; 129():258-268. PubMed ID: 34048974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition.
    Chen Z; Vallega KA; Chen H; Zhou J; Ramalingam SS; Sun SY
    Pharmacol Res; 2022 Jan; 175():105998. PubMed ID: 34826601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degradation of Mcl-1 through GSK-3β Activation Regulates Apoptosis Induced by Bufalin in Non-Small Cell Lung Cancer H1975 Cells.
    Kang XH; Zhang JH; Zhang QQ; Cui YH; Wang Y; Kou WZ; Miao ZH; Lu P; Wang LF; Xu ZY; Cao F
    Cell Physiol Biochem; 2017; 41(5):2067-2076. PubMed ID: 28419994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
    Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer.
    Zhou J; Wang X; Li Z; Wang F; Cao L; Chen X; Huang D; Jiang R
    Cell Death Dis; 2024 Sep; 15(9):644. PubMed ID: 39227379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expression.
    Jiang Y; Zhuo X; Wu Y; Fu X; Mao C
    Biochim Biophys Acta Mol Cell Res; 2022 Jan; 1869(1):119144. PubMed ID: 34599981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.
    Ichihara E; Hotta K; Ninomiya K; Kubo T; Ohashi K; Rai K; Tanaka H; Tabata M; Maeda Y; Kiura K
    Lung Cancer; 2019 Jun; 132():54-58. PubMed ID: 31097094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxus chinensis var. mairei (Lemée et Lévl) Cheng et L.K. Fu overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer via suppression of ERK1/2-related cholesterol biosynthesis.
    Dai S; Zhang GC; Xiang Y; Liu Y; Wang H; Zhao F; Shu Q
    J Ethnopharmacol; 2024 Nov; 334():118586. PubMed ID: 39032664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tanshinone IIA acts as a regulator of lipogenesis to overcome osimertinib acquired resistance in lung cancer.
    Cao L; Qin Z; Yu T; Bai X; Jiang S; Wang D; Ning F; Huang M; Jin J
    Biochem Pharmacol; 2024 Jun; 224():116207. PubMed ID: 38621425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.
    Gu J; Yao W; Shi P; Zhang G; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer; 2020 Aug; 126(16):3788-3799. PubMed ID: 32497272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.